Thread: Studies identify cell-signaling pathway alterations responsible for melanoma drug res

Genomic profiling of treatment-resistant, BRAF-mutated melanomas revealed multiple gene alterations, mostly involving a cell-signaling pathway called the MAPK pathway, and more potent forms of existing drugs and drugs targeting the protein ERK may provide durable control of the disease, according to two studies published in Cancer Discovery, a journal of the American Association for Cancer Research."Currently there is not enough known about the genetic and molecular changes that may causedrug resistance in melanomas harboring BRAF mutations," said Levi A. Garraway, M.D., Ph.D.

More...